Agenus (AGEN)

• Market cap: $129M
• 1 day: -7.11%
• 5 days: -4.53%
• 1 month: -14.45%
• 3 months: -15.4%
• 6 months: -21.37%
• Year to date: 22.65%
• 1 year: 23.05%
• 5 years: -94.74%
• 10 years: -95.02%
• Sector: Healthcare
• Industry: Biotechnology

About: Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Employees: 316